Chapter 19 - Autoimmune myelopathies
Introduction
Autoimmune myelopathies represent a diverse group of disorders that affect the spinal cord and are unified by their immune-mediated mechanism. Rapid recognition of autoimmune myelopathies is important given the unforgiving nature of spinal cord injury, brisk accumulation of disability in some, and the potential for early appropriate treatment to improve outcomes. However, there are many nonautoimmune causes of myelopathy which present similarly and will also be discussed in this chapter. Idiopathic transverse myelitis is a term that has been used historically to describe acute-subacute inflammatory myelopathies of uncertain cause, but recent discoveries have allowed many of these myelopathies to be categorized into specific etiologies, despite some remaining idiopathic. Autoimmune myelopathies may occur as a primary autoimmune phenomenon (e.g., longitudinally extensive transverse myelitis in neuromyelitis optica (NMO) or its spectrum disorders (NMOSD)), a postinfectious phenomenon (e.g., acute disseminated encephalomyelitis (ADEM)), or as a paraneoplastic autoimmune disorder associated with an underlying cancer (paraneoplastic myelopathy). Other immune-related myelopathies within this umbrella term include spinal cord sarcoidosis and myelopathies from multiple sclerosis (MS). The recent discovery of multiple novel autoantibody markers of autoimmune myelopathies (e.g., aquaporin-4-IgG (AQP-4-IgG) as a biomarker of NMO/NMOSD) improved our understanding of autoimmune myelopathies and allowed more precise classification. Furthermore, it has allowed the development and application of more targeted treatments which have the potential to be more efficacious and less toxic than current treatments.
Section snippets
Diagnostic criteria and categorization of autoimmune myelopathies
Autoimmune myelopathies do not have specific diagnostic criteria, but do encompass a wide variety of spinal cord diseases, some with their own diagnostic criteria, including: MS (Polman et al., 2011), NMO (Wingerchuk et al., 2006), idiopathic transverse myelitis (Transverse Myelitis Consortium Working Group, 2002), paraneoplastic neurologic syndromes (Graus et al., 2004), and neurosarcoidosis (Terushkin et al., 2010).
Demographics
Similar to all autoimmune diseases, autoimmune myelopathies are more common in
Risk factors
A strong personal or family history of autoimmunity is a clue to an autoimmune myelopathy. The presence of concurrent weight loss, deep venous thrombosis, or risk factors for cancer (long history of smoking; known prior cancer) gives a clue to a possible paraneoplastic autoimmune myelopathy, although neoplastic myelopathies or iatrogenic myelopathies (e.g., radiation myelopathy) should also be considered. The presence of recent or intercurrent infection or symptoms supportive of that (fevers,
MRI spine
Magnetic resonance imaging (MRI) of the spine (cervical and/or thoracic) with and without gadolinium is recommended in all patients with myelopathy. The first step is to exclude a compressive cause. The findings on MRI are a very powerful tool in guiding clinicians towards the correct diagnosis.
Differential diagnosis
Idiopathic transverse myelitis is a diagnosis of exclusion and a wide variety of investigations may be necessary to exclude other causes. The presence of recent fever, chills, night sweats, rash, or an immunocompromised state may give a clue to an infectious myelitis and a list of infectious causes is outlined in Table 19.1, Table 19.2. Involvement of the gray matter in the spinal cord may give a clue to West Nile virus and was also seen with an outbreak of enterovirus D68 in the USA in 2015
Serum and cerebrospinal fluid (CSF) evaluation
The diagnostic approach to transverse myelitis is complicated and a diagnostic algorithm is provided in Figure 19.9 (Frohman and Wingerchuk, 2010). Laboratory investigations in autoimmune myelopathies are important both to exclude treatable diseases that mimic autoimmune myelopathies but also to look for markers of systemic or organ-specific autoimmunity (Table 19.4). Given the broad differential diagnosis of myelopathies (Table 19.1, Table 19.2), there is no one diagnostic evaluation that fits
Autoimmune myelopathies in patients with systemic autoimmune disease or markers of systemic autoimmunity
Spinal cord disease has been described in a number of systemic autoimmune diseases, including lupus, Sjögren's syndrome, Behçet’s, and scleroderma. Autoimmune myelopathies have also been described with antiphospholipid antibody syndrome, although some of these may be ischemic from the associated hypercoagulable state (Flanagan et al., 2014c). Certain clinical clues and helpful diagnostic tests are outlined in Table 19.4. Testing for one or more of the following markers of extraneurologic
Spinal cord biopsy and pathology of autoimmune myelopathies
Given its eloquent location and the risk of severe morbidity during surgery, spinal cord biopsy is usually restricted to patients with prominent disability in whom diagnostic uncertainty remains despite extensive investigations. A trial of empiric treatment (usually with corticosteroids) is often recommended prior to pursuing biopsy; however, spinal cord biopsy is appropriate in certain situations, particularly when the biopsy may change management (e.g., by detecting a primary intramedullary
Cancer investigation
The most common cancers associated with paraneoplastic isolated myelopathies are small-cell lung and breast (Flanagan et al., 2011b). In addition to physical examination to look for these cancers, we recommend a mammogram in women and body computed tomography (CT) or positron emission tomography (PET)/CT scan in all to assess for cancer; body PET may improve the sensitivity for the detection of cancer in those at high risk (McKeon et al., 2010). Other sex-specific tests should not be
AQP-4-IgG-seropositive autoimmune myelopathies
AQP-4-IgG is a member of immunoglobulin subclass 1 and is produced mostly by B-cell derivatives (plasma cells and their precursors, plasmablasts). Antibody production depends on T-cell help, often in the form of Th17 cells, which help activate B cells in lymph nodes to differentiate into memory B cells (CD19+, CD27+, CD38–), plasmablasts (CD19intermediate, CD27+, CD38+), and plasma cells (CD19–, CD27+, CD38+) (Chihara et al., 2011). In this study, AQP4-IgG antibodies were made by plasmablasts
Therapeutic approach
The general approach for using immunotherapy in patients with autoimmune myelopathies is a “three M” approach: (1) maximize reversibility with acute treatments; (2) maintain benefits and prevent relapses; and (3) minimize side effects. The treatment may vary depending on the type of disease, underlying autoantibody, and presence or absence of cancer.
Conclusions and future direction
MRI is a powerful tool in narrowing the differential diagnosis of autoimmune myelopathies and its mimics. A summary of the MRI T2-signal and gadolinium enhancement patterns that help distinguish autoimmune myelopathies and some common mimics are outlined in Fig. 19.11, Fig. 19.12 respectively. In addition to the need for better appreciation of the radiologic features of myelopathy, there is also a need for randomized controlled trials in autoimmune myelopathies to help guide treatments. We
Disclosures
Dr Flanagan has no disclosures to report.
References (92)
- et al.
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy
Mayo Clin Proc
(2013) - et al.
Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures
J Neurol Sci
(2011) - et al.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lancet
(2004) - et al.
Differential diagnosis and diagnostic criteria for multiple sclerosis: application and pitfalls
- et al.
A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA
Lancet
(2015) - et al.
Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels
J Clin Neurosci
(2011) - et al.
Aquaporin 4 and neuromyelitis optica
Lancet Neurol
(2012) - et al.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
Lancet Neurol
(2013) - et al.
Multiple sclerosis and the spinal cord
Neurol Clin
(2013) - et al.
Spinal cord neurosarcoidosis
Am J Med Sci
(2014)
Clinical and magnetic resonance imaging manifestations of neurosarcoidosis
Semin Arthritis Rheum
Neurologic presentations of sarcoidosis
Neurol Clin
Management of spasticity from spinal cord dysfunction
Neurol Clin
The spectrum of neuromyelitis optica
Lancet Neurol
Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature
J Oncol Pharm Pract
Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study
BMC Neurol
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders
Neurology
Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein
J Neurol Neurosurg Psychiatry
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group
N Engl J Med
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
N Engl J Med
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Proc Natl Acad Sci U S A
Spinal cord biopsy: a review of 38 cases
Neurosurgery
A benign form of neuromyelitis optica: does it exist?
Arch Neurol
An open label study of the effects of rituximab in neuromyelitis optica
Neurology
Posterior reversible encephalopathy syndrome with spinal cord involvement
Neurology
Neuropathic pruritus (itch) in neuromyelitis optica
Mult Scler
Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients
Mult Scler
Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
Cochrane Database Syst Rev.
Neuromyelitis optica spectrum disorders
Curr Neurol Neurosci Rep
Autoimmune myelopathies
Continuum
Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues
Neurology
Primary intramedullary spinal cord lymphoma
Neurology
Secondary intramedullary spinal cord non-Hodgkin's lymphoma
J Neurooncol
Specific pattern of gadolinium enhancement in spondylotic myelopathy
Ann Neurol
Clinical reasoning: a 55-year-old man with weight loss, ataxia, and foot drop
Neurology
Anterior spinal artery infarction causing man-in-the-barrel syndrome
Neurol Clin Pract
Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders
JAMA Neurol
Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy
Neurol Clin Pract
Motor neuron syndromes in cancer patients
Ann Neurol
Clinical practice. Transverse myelitis
N Engl J Med
AQP4 autoantibody assay performance in clinical laboratory service
Neurol Neuroimmunol Neuroinflammation
Clinical presentation and prognostic factors of spinal dural arteriovenous fistulas: an overview
Neurosurg Focus
Recommended diagnostic criteria for paraneoplastic neurological syndromes
J Neurol Neurosurg Psychiatry
Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica
Ann Neurol
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2
J Exp Med
Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells
Arch Neurol
Cited by (31)
The Role of MRI in Differentiating Demyelinating and Inflammatory (not Infectious) Myelopathies
2023, Seminars in Ultrasound, CT and MRIDistinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to “overlap” cases
2022, Journal of NeuroimmunologyCitation Excerpt :Lesions tend to involve the cervical and upper thoracic regions with preferential dorsal column involvement. In 77% of sarcoid myelopathies, there is a longitudinally extensive transverse myelitis (LETM) which can extend for 3 or more spinal segments (Flanagan, 2016; Arun et al., 2020). Differentials for LETM lesions should also include NMOSD, MOG-antibody associated disease, paraneoplastic disease and autoimmune astrocytopathy with glial fibrillary acidic protein (GFAP-IgG) in which LETM may present as a component of a meningoencephalomyelitis (Flanagan et al., 2017).
Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?
2020, Journal of the Neurological SciencesAcute demyelinating disorder by parvovirus B19
2020, Enfermedades Infecciosas y Microbiologia ClinicaNeurotoxocariasis
2020, Advances in ParasitologyCitation Excerpt :In particular MRI findings related to the spinal cord involvement, the most common presentation of NT, are indistinguishable from other inflammatory and infective myelitis. Furthermore, almost all cases of NT reported in literature have been treated with anti-helminthic drugs in association with corticosteroids and the majority of inflammatory myelopathy such as, autoimmune myelopathy (e.g., aquaporin-4-IgG seropositive neuromyelitis optica, multiple sclerosis, paraneoplastic myelopathies) (Flanagan, 2016) are responsive to corticosteroids treatment. Thus, the clinical and radiological improvement, considered an important criterion for the diagnosis of NT and reported in almost all cases, could not be univocally attributable to the anti-helminthic drugs.
Clinical characteristics of patients with paraneoplastic myelopathy
2019, Journal of NeuroimmunologyCitation Excerpt :Whole-body PET scan was performed in 2 patients. Extensive examinations were done to exclude competing diagnoses, including progressive myelopathy such as neurosarcoidosis (which did not fit the diagnostic criteria (Zajicek et al., 1999; Flanagan, 2016), primary or metastatic neoplastic myelopathy (patients with spinal lesions were evaluated by PET (Flanagan et al., 2012; Flanagan et al., 2011a, 2011b, 2011c), other inflammatory myelopathy such as neuromyelitis optica (NMO) (progressive NMO clinical course is rare (Wingerchuk et al., 2015) and progressive solitary sclerosis (Keegan et al., 2016), compressive myelopathy (Flanagan et al., 2014), infectious myelopathy, nutritional myelopathy, toxic myelopathy and inherited spastic paraparesis. For patients with negative onconeural antibodies, spinal vascular malformations, especially spinal dural arteriovenous fistulas (AVF), is needed to pay attention, which may present as progressive myelopathy with 0.5 months to 3 years duration (Ma et al., 2018).